Introduction {#Sec1}
============

Breast cancer (BC) is a major burden for women's health \[[@CR1]\]. Survival has improved substantially over the past half century due to earlier detection and advanced treatment modalities, for example in the Netherlands, 10-year survival of a first primary BC improved from 40% in 1961--1970 to 79% in 2006--2010 \[[@CR2]\]. Consequently, increasing numbers of BC survivors are at risk to develop a new primary tumor in the opposite (contralateral) breast, with subsequent treatment and potentially less favorable prognosis \[[@CR3]\]. BC survivors are more likely to develop contralateral breast cancer (CBC) compared to healthy women to develop a first primary BC \[[@CR4]\].

Women at elevated CBC risk have been identified to be *BRCA1/2* and *CHEK2* c.1100del mutation carriers and to have a BC family history, particularly a family history of bilateral BC \[[@CR5]--[@CR10]\]. For *BRCA1/2* mutation carriers, in whom CBC risk is high, contralateral preventive mastectomy (CPM) is often offered \[[@CR11]\]. However, the average risk of CBC among all first BC survivors is still relatively low, with an incidence of \~ 0.4% per year \[[@CR12]--[@CR14]\]. Despite this, in recent years, CPM frequency has increased among women in whom CBC risk is low \[[@CR15]\]. For these reasons, there is an urgent need for improved individualized prediction of CBC risk, both to facilitate shared decision-making of physicians and women regarding treatment and prevention strategies for those at high CBC risk and to avoid unnecessary CPM or surveillance mammography after first primary BC when CBC risk is low.

To our knowledge, only one specific CBC risk prediction model (CBCrisk) has been developed to date. CBCrisk used data on 1921 CBC cases and 5763 matched controls with validation in two independent US studies containing a mix of invasive and in situ BC \[[@CR16], [@CR17]\]. Moreover, the level of prediction performance measures such as calibration and discrimination needed for a CBC risk prediction to be clinically useful have not yet been addressed \[[@CR18]\].

Our aim was twofold: first, to develop and validate a CBC risk prediction model using a large international series of individual patient data including 132,756 patients with a first primary invasive BC between 1990 and 2013 from multiple studies in Europe, USA, and Australia with 4682 incident CBCs, and second, to evaluate the potential clinical utility of the model to support decision-making.

Material and methods {#Sec2}
====================

Study population {#Sec3}
----------------

We used data from five main sources: three studies from the Netherlands, 16 studies from the Breast Cancer Association Consortium (BCAC), and a cohort from the Netherlands Cancer Registry \[[@CR19]--[@CR22]\]. For details regarding data collection and patient inclusion, see Additional file [1](#MOESM1){ref-type="media"}: Data and patient selection and Table S1, and Additional file [1](#MOESM1){ref-type="media"}: Table S2. We included female patients with invasive non-metastatic first primary BC with no prior history of cancer (except for non-melanoma skin cancer). The studies were either population- or hospital-based series; most women were of European-descent. We only included women diagnosed after 1990 to have a population with diagnostic and treatment procedures likely close to modern practice and at the same time sufficient follow-up to study CBC incidence; in total 132,756 women from 20 studies were included. All studies were approved by the appropriate ethics and scientific review boards. All women provided written informed consent or did not object to secondary use of clinical data in accordance with Dutch legislation and codes of conduct \[[@CR23], [@CR24]\].

Available data and variable selection {#Sec4}
-------------------------------------

Several factors have been shown or suggested to be associated with CBC risk, including age at first BC, family history for BC, *BRCA1/2* and *CHEK2* c.1100del mutations, body mass index (BMI), breast density change, (neo)adjuvant chemotherapy, endocrine therapy, CPM, and characteristics of the first BC such as histology (lobular vs ductal), estrogen receptor (ER) status, lymph node status, tumor size, and TNM stage \[[@CR5], [@CR9], [@CR12], [@CR25]--[@CR36]\]. The choice of factors to include in the analyses was determined by evidence from literature, availability of data in the cohorts, and current availability in clinical practice. We extracted the following information: *BRCA1/2* germline mutation, (first degree) family history of primary BC, and regarding primary BC diagnosis: age, nodal status, size, grade, morphology, ER status, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, administration of adjuvant and/or neoadjuvant chemotherapy, adjuvant endocrine therapy, adjuvant trastuzumab therapy, radiotherapy. We excluded PR status and TNM stage of the primary BC due to collinearity with ER status and the size of the primary tumor, respectively. In the current clinical practice, only patients with ER-positive tumors receive endocrine therapy and only patients with HER2-positive tumors receive trastuzumab; these co-occurrences were considered in the model by using composite categorical variables. More information is available online about the factors included in the analyses (Additional file [1](#MOESM1){ref-type="media"}: Data patient selection and Additional file [2](#MOESM2){ref-type="media"}: Figure S1), follow-up per dataset, and study design (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

Statistical analyses {#Sec5}
--------------------

All analyses were performed using SAS (SAS Institute Inc., Cary, NC, USA) and R software \[[@CR37]\].

Primary endpoint, follow-up, and predictors {#Sec6}
-------------------------------------------

The primary endpoint in the analyses was in situ or invasive metachronous CBC. Follow-up started 3 months after invasive first primary BC diagnosis, in order to exclude synchronous CBCs, and ended at date of CBC, distant metastasis (but not at loco-regional relapse), CPM, or last date of follow-up (due to death, being lost to follow-up, or end of study), whichever occurred first. The follow-up of 27,155 (20.4%) women from the BCAC studies, recruited more than 3 months after diagnosis of the first primary BC (prevalent cases), started at recruitment (left truncation). Distant metastasis and death due to any cause were considered as competing events. Patients who underwent CPM during the follow-up were censored because the CBC risk was almost zero after a CPM \[[@CR38]\]. Missing data were multiply imputed by chained equations (MICE) to avoid loss of information due to case-wise deletion \[[@CR39], [@CR40]\]. Details about the imputation model, strategy used, and the complete case analysis are provided in Additional file [1](#MOESM1){ref-type="media"}: Multiple Imputation of missing values, complete case analysis, and model diagnostics and baseline recalibration and Additional file [1](#MOESM1){ref-type="media"}: Tables S3 and S4.

Model development and validation {#Sec7}
--------------------------------

For model development, we used a multivariable Fine and Gray model regression to account for death and distant metastases as competing events \[[@CR41], [@CR42]\]. Heterogeneity of baseline risks between studies was taken into account using the study as a stratification term. A stratified model allows the baseline subdistribution hazard to be different across the studies, and parameter estimation is performed by maximization of the partial likelihood per study. A Breslow-type estimator was used to estimate the baseline cumulative subdistribution hazard per study. The assumption of proportional subdistribution hazards was graphically checked using Schoenfield residuals \[[@CR43]\]. The resulting subdistributional hazard ratios (sHRs) and corresponding 95% confidence intervals (CI) were pooled from the 10 imputed data sets using Rubin's rules \[[@CR44]\]. We built a nomogram for estimating the 5- and 10-year cumulative incidence of CBC as a graphical representation of the multivariable risk prediction model \[[@CR45]\].

The validity of the model was investigated by leave-one-study-out cross-validation, i.e., in each validation step, all studies are used except one in which the validity of the model is evaluated \[[@CR46], [@CR47]\]. Since the ABCS study and some studies from BCAC had insufficient CBC events required for reliable validation, we used the geographic area as unit of splitting. We had 20 studies in five main sources: 17 out of 20 studies that were combined in 4 geographic areas. In total, 3 studies and 4 geographic areas were used to assess the prediction performance of the model (see Additional file [1](#MOESM1){ref-type="media"}: Leave-one-study-out cross-validation and Additional file [1](#MOESM1){ref-type="media"}: Table S5, \[[@CR47], [@CR48]\].

The performance of the model was assessed by discrimination ability to differentiate between patients who experienced CBC and those who did not, and by calibration, which measures the agreement between observed and predicted CBC risk. Discrimination was quantified by time-dependent area under the ROC curves (AUCs) based on Inverse Censoring Probability Weighting at 5 and 10 years \[[@CR49], [@CR50]\]. In the presence of competing risks, the R package timeROC provides two types of AUC according to a different definition of time-dependent cases and controls. AUCs were calculated considering a patient who developed a CBC as a case and a patient free of any event as a control at 5 and 10 years \[[@CR50]\]. Values of AUCs close to 1 indicate good discriminative ability, while values close to 0.5 indicated poor discriminative ability. Calibration was assessed by the calibration-in-the-large and slope statistic \[[@CR51]\]. Calibration-in-the-large lower or higher than 0 indicates that prediction is systematically too high or low, respectively. A calibration slope of 1.0 indicates good overall calibration; slopes below (above) 1.0 indicate over (under) estimation of risk by the model.

To allow for heterogeneity among studies, a random-effect meta-analysis was performed to provide summaries of discrimination and calibration performance. The 95% prediction intervals (PI) indicated the likely range for the prediction performances of the model in a new dataset. Further details about the validation process are provided in Additional file [1](#MOESM1){ref-type="media"}: Leave-one-study-out cross-validation.

Clinical utility {#Sec8}
----------------

The clinical utility of the prediction model was evaluated using decision curve analysis (DCA) \[[@CR52], [@CR53]\]. Such a decision may apply to more or less intensive screening and follow-up or to decision of a CPM. The key part of the DCA is the net benefit, which is the number of true-positive classifications (in this example: the benefit of CPM to a patient who would have developed a CBC) minus the number of false-positive classifications (in this example: the harm of unnecessary CPM in a patient who would not have developed a CBC). The false positives are weighted by a factor related to the relative harm of a missed CBC versus an unnecessary CPM. The weighting is derived from the threshold probability to develop a CBC using a defined landmark time point (e.g., CBC risk at 5 or 10 years) \[[@CR54]\]. For example, a threshold of 10% implies that CPM in 10 patients, of whom one would develop CBC if untreated, is acceptable (thus performing 9 unnecessary CPMs). The net benefit of a prediction model is traditionally compared with the strategies of treat all or treat none. Since the use of CPM is generally only suggested among *BRCA1/2* mutation carriers, for a more realistic illustration, the decision curve analysis was reported among *BRCA1/2* mutation carriers and non-carriers \[[@CR55]\]. See Additional file [1](#MOESM1){ref-type="media"}: Clinical utility for details.

Results {#Sec9}
=======

A total of 132,756 invasive primary BC women diagnosed between 1990 and 2013, with 4682 CBC events, from 20 studies, were used to derive the model for CBC risk (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Median follow-up time was 8.8 years, and CBC cumulative incidences at 5 and 10 years were 2.1% and 4.1%, respectively. Details of the studies and patient, tumor, and treatment characteristics are provided in Additional file [1](#MOESM1){ref-type="media"}: Table S6. The multivariable model with estimates for all included factors is shown in Table [1](#Tab1){ref-type="table"} and Additional file [3](#MOESM3){ref-type="media"}. *BRCA1/2* germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk. Table 1Multivariable subdistribution hazard model for contralateral breast cancer riskFactor (category) at primary breast cancerMultivariable analysissHR95% CIAge, *years*0.68\*0.62--0.74\*Family history (yes versus no)1.351.27--1.45*BRCA* mutation *BRCA1* versus non-carrier3.683.34--4.07 *BRCA2* versus non-carrier2.562.36--2.78Nodal status (positive versus negative)0.870.80--0.93Tumor size, *cm* 2.5 versus ≤ 20.950.89--1.02 \> 5 versus ≤ 21.140.99--1.31Morphology (lobular including mixed versus ductal including others)1.231.14--1.34Grade Moderately differentiated versus well differentiated0.890.82--0.96 Poorly differentiated versus well differentiated0.750.70--0.82Chemotherapy (yes versus no)0.770.70--0.84Radiotherapy to the breast (yes versus no)1.010.95--1.08ER (positive or negative)/endocrine therapy (yes or no) Negative/no versus positive/yes1.431.30--1.57 Positive/no versus positive/yes1.751.61--1.90HER2 (positive or negative)/trastuzumab therapy (yes or no) Negative/no versus positive/yes1.080.93--1.27 Positive/no versus positive/yes0.990.83--1.18*sHR* subdistributional hazard ratio, *CI* confidence interval, *ER* estrogen receptor, *HER2* human epidermal growth factor receptor 2. \*Age was parameterized as a linear spline with one interior knot at 50 years. For representation purposes, we here provide the sHR for the 75th versus the 25th percentile. For more details about age parameterization, see also Additional file [3](#MOESM3){ref-type="media"}: Supplementary Methods

The prediction performance of the main model (PredictCBC, version 1A) based on the leave-one-study-out cross-validation method is shown in Fig. [1](#Fig1){ref-type="fig"}. The AUC at 5 years was 0.63 (95% confidence interval (CI): 0.58--0.67; 95% prediction interval (PI): 0.52--0.74)); the AUC at 10 years was also 0.63 (95% CI: 0.59--0.66; 95% PI: 0.53--0.72). Calibrations showed some indications of overestimation of risk. The calibration-in-the-large was − 0.13 (95% CI: -0.66--0.40; 95% PI: -1.62--1.37). The calibration slope was 0.90 (95% CI: 0.79--1.02; 95% PI: 0.73--1.08) in the cross-validation. Calibration plots are provided in Additional file [2](#MOESM2){ref-type="media"}: Figure S2 and S3. Fig. 1Analysis of predictive performance in leave-one-study-out cross-validation. **a**, **b** The discrimination assessed by a time-dependent AUC at 5 and 10 years, respectively. **c** The calibration accuracy measured with calibration-in-the-large. **d** The calibration accuracy measured with calibration slope. The black squares indicate the estimated accuracy of a model built using all remaining studies or geographic areas. The black horizontal lines indicate the corresponding 95% confidence intervals of the estimated accuracy (interval whiskers). The black diamonds indicate the mean with the corresponding 95% confidence intervals of the predictive accuracy, and the dashed horizontal lines indicate the corresponding 95% prediction intervals

The nomogram representing a graphical tool for estimating the CBC cumulative incidence at 5 and 10 years based on our model and the estimated baseline of the Dutch Cancer Registry is shown in Fig. [2](#Fig2){ref-type="fig"}. In the nomogram, the categories of each factor are assigned a score using the topmost "Points" scale, then all scores are summed up to obtain the "Total points", which relate to the cumulative incidence of CBC. The formulae of the models (PredictCBC-1A and 1B) providing the predicted cumulative incidence are given in Additional file [1](#MOESM1){ref-type="media"}: Formula to estimate the CBC risk and formula to estimate CBC risk in patients not tested for *BRCA*. Fig. 2Nomogram for the prediction of 5- and 10-year contralateral breast cancer cumulative incidence. The 5- and 10-year contralateral breast cancer cumulative incidence is calculated by taking the sum of the risk points, according to patient, first primary breast cancer tumor, and treatment characteristics. For each factor, the number of associated risk points can be determined by drawing a vertical line straight up from the factor's corresponding value to the axis with risk points (0--100). The total points axis (0--350) is the sum of the factor's corresponding values determined by every individual patient's characteristics. Draw a line straight down from the total points axis to find the 5- and 10-year cumulative incidence.PBC primary breast cancer, ER estrogen receptor status, HER2 human epidermal growth factor receptor 2, yr year

The DCAs for preventive contralateral mastectomy showed the potential clinical utility of PredictCBC-1A between thresholds of 4--10% 10-year CBC risk for *BRCA1/2* mutation carriers and non-carriers (Table [2](#Tab2){ref-type="table"} and Additional file [3](#MOESM3){ref-type="media"}). For example, if we find it acceptable that one in 10 patients for whom a CPM is recommended develops a CBC, a risk threshold of 10% may be used to define high and low risk *BRCA1/2* mutation carriers based on the absolute 10-year CBC risk prediction estimated by the model. Compared with a strategy recommending CPM to all carriers of a mutation in *BRCA1*/2, this strategy avoids 161 CPMs per 1000 patients. In contrast, almost no non *BRCA1/2* mutation carriers reach the 10% threshold (the general BC population, Fig. [3](#Fig3){ref-type="fig"}). The decision curves provide a comprehensive overview of the net benefit for a range of harm-benefit thresholds at 10-year CBC risk (Fig. [4](#Fig4){ref-type="fig"}). Table 2Clinical utility of the 10-year contralateral breast cancer risk prediction model. At the same probability threshold, the net benefit is exemplified in *BRCA1/2* mutation carriers (for avoiding unnecessary CPM) and non-carriers (performing necessary CPM)Probability threshold, *p*~t~ (%)Unnecessary CPMs needed to prevent one CBC\**BRCA1/2* mutation carriersNon-carriersNet benefit versus treat all patients with CPM (per 1000)Avoided unnecessary CPMs per 1000 patientsNet benefit versus treat none (per 1000)Performed necessary CPMs per 1000 patients424.00.00.03.993.6519.00.00.02.139.9615.70.11.60.57.8713.31.925.20.11.3811.55.563.30.00.0910.110.7108.20.00.0109.017.9161.10.00.0*CPM* contralateral preventive mastectomy, *CBC* contralateral breast cancer. \*The number of unnecessary contralateral mastectomies needed to prevent a CBC is calculated by (1 − *p*~t~)/*p*~t~. See also Additional file [3](#MOESM3){ref-type="media"}: Methods Fig. 3Density distribution of 10-year predicted contralateral breast cancer absolute risk within non-carriers (area with black solid lines) and *BRCA1/2* mutation carriers (area with black dashed lines) Fig. 4Decision curve analysis at 10 years for the contralateral breast cancer risk model including *BRCA* mutation information. **a** The decision curve to determine the net benefit of the estimated 10-year predicted contralateral breast cancer (CBC) cumulative incidence for patients without a *BRCA1/2* gene mutation using the prediction model (dotted black line) compared to not treating any patients with contralateral preventive mastectomy (CPM) (black solid line). **b** The decision curve to determine the net benefit of the estimated 10-year predicted CBC cumulative incidence for *BRCA1/2* mutation carriers using the prediction model (dotted black line) versus treating (or at least counseling) all patients (gray solid line). The *y*-axis measures net benefit, which is calculated by summing the benefits (true positives, i.e., patients with a CBC who needed a CPM) and subtracting the harms (false positives, i.e., patients with CPM who do not need it). The latter are weighted by a factor related to the relative harm of a non-prevented CBC versus an unnecessary CPM. The factor is derived from the threshold probability to develop a CBC at 10 years at which a patient would opt for CPM (e.g., 10%). The *x*-axis represents the threshold probability. Using a threshold probability of 10% implicitly means that CPM in 10 patients of whom one would develop a CBC if untreated is acceptable (9 unnecessary CPMs, harm to benefit ratio 1:9)

Decision curves for CBC risk at 5 year and the corresponding clinical utility are provided in Additional file [2](#MOESM2){ref-type="media"}: Figure S4 and Additional file [1](#MOESM1){ref-type="media"}: Table S7, respectively.

We also derived a risk prediction model (PredictCBC, version 1B) omitting *BRCA* status to provide CBC risk estimates for first BC patients not tested for *BRCA1/2* mutations. This model has slightly lower prediction performance; AUC at 5 and 10 years was both 0.59 (at 5 years: 95% CI: 0.54--0.63, 95% PI: 0.46--0.71; at 10 years: 95% CI: 0.56--0.62, 95% PI: 0.52--0.66), calibration-in-the-large was − 0.17 (95% CI: -0.72--0.38; 95% PI: -1.70--1.36), and calibration slope was 0.81 (95% CI 0.63--0.99; 95% PI: 0.50--1.12) (Additional file [1](#MOESM1){ref-type="media"}: Results of the prediction model without *BRCA* mutation). Details of development, validation, and clinical utility are provided in Additional file [1](#MOESM1){ref-type="media"}: Tables S8--S10 and Figure S5--S10.

In a sensitivity analysis (see Additional file [1](#MOESM1){ref-type="media"}: Assessment of limited information of CPM), we studied the impact of CPM on our results using two studies, in which CPM information was (almost) completely available. The lack of CPM information on cumulative incidence estimation hardly affected the results of our analyses (Additional file [2](#MOESM2){ref-type="media"}: Figure S11).

Discussion {#Sec10}
==========

Using established risk factors for CBC which are currently available in clinical practice, we developed PredictCBC, which can be used to calculate 5- and 10-year absolute CBC risk. The risk prediction model includes carriership of *BRCA1/2* mutations, an important determinant of CBC risk in the decision-making process \[[@CR6]\].

The calibration of the model was reasonable and discrimination moderate within the range of other tools commonly used for routing counseling and decision-making in clinical oncology for primary BC risk \[[@CR56]--[@CR59]\]. As expected, the prediction accuracy was lower when we omitted the *BRCA* mutation carrier status although the prevalence of *BRCA* mutations among BC patients is quite low (2--4%) \[[@CR60], [@CR61]\].

In the breast cancer population, CBC is a relatively uncommon event (\~ 0.4% per year) and difficult to predict. Therefore, physicians should carefully consider which patients should consider CPM using a prediction model \[[@CR62]\]. The current clinical recommendations of CPM are essentially based on the presence of a mutation in the *BRCA1/2* genes. Based on the risk distribution defined by the current model (Fig. [3](#Fig3){ref-type="fig"}), this is a reasonable approach: essentially no non-carrier women reach a 10% risk 10-year threshold. However, more than 50% of carriers do not reach this threshold either, suggesting that a significant proportion of *BRCA1/2* carriers might be spared CPM. Contralateral surveillance mammography may also be avoided although detection and knowledge of recurrences may be necessary for better defined individualized follow-up and patient-tailored treatment strategies \[[@CR63], [@CR64]\].

CBC risk patterns and factors were identified previously in a large population-based study with 10,944 CBC of 212,630 patients from the Surveillance, Epidemiology and End Results (SEER) database diagnosed from 1990 to 2013 \[[@CR65]\]. However, SEER does not include details of endocrine treatment and chemotherapy, therapies administrated to reduce recurrences and CBCs \[[@CR13], [@CR66]\]. Furthermore, in this study, the model was not validated or evaluated based on prediction accuracy, nor was a tool provided. Another study provided general guidelines for CPM by calculating the lifetime risk of CBC based on a published systematic review of age at first BC, *BRCA1/2* gene mutation, family history of BC, ER status, ductal carcinoma in situ, and oophorectomy \[[@CR34], [@CR67]\]. However, the authors specified that the calculation of the CBC lifetime risk should be considered only as a guide for helping clinicians to stratify patients into risk categories rather than a precise tool for the objective assessment of the risk.

Only one other prediction model (CBCrisk) has been developed and validated using data of 1921 CBC cases and 5763 matched controls \[[@CR16]\]. External validation of CBCrisk of two independent datasets using 5185 and 6035 patients with 111 and 117 CBC assessed a discrimination between 0.61 and 0.65 \[[@CR17]\]. The discrimination of our PredictCBC model at 5 and 10 years was similar; however, the geographic diversity of the studies gave a more complete overview of external validity \[[@CR47]\]. Moreover, we showed the net benefit of our model using decision curve analysis since standard performance metrics of discrimination, calibration, sensitivity, and specificity alone are insufficient to assess the clinical utility \[[@CR18], [@CR53]\].

Some limitations of our study must be recognized. First, reporting of CBC was not entirely complete in all studies and information about CPM was limited in most datasets, which may have underestimated the cumulative incidence, although the overall 10-year cumulative incidence of 4.1% is in line with other data \[[@CR5], [@CR34]\]. Second, some women included in the Dutch studies (providing specific information on family history, *BRCA* mutation, or CPM) were also present in our selection of the Netherlands Cancer Registry population. Privacy and coding issues prevented linkage at the individual patient level, but based on the hospitals from which the studies recruited, and the age and period criteria used, we calculated a maximum potential overlap of 3.4%. Third, in the US and Australian datasets, the prediction performance was uncertain due to the limited sample size and missing values. Moreover, some important predictors such as family history and especially *BRCA* mutation status were only available in a subset of the women (from familial- and unselected hospital-based studies) and patients with data on *BRCA* mutation status might have been insufficiently represented for tested populations and further development and validation of PredictCBC-1A will be necessary. However, although *BRCA1/2* mutation information was unavailable in 94% of our data, the approach of the imputation led to consistently good performing models \[[@CR68]--[@CR70]\]. The remaining factors were quite complete: \~ 79% of patients had at most one missing factor, which provided good imputation diagnostic performances. Since most BC patients are not currently tested in the clinical practice for *BRCA1/2* mutations, we assessed the clinical utility of PredictCBC version 1B to provide individualized CBC risk estimates for first BC patients not tested for *BRCA1/2* germline mutations \[[@CR60], [@CR71]\]. Our PredictCBC version 1B model provides less precise estimates, but may be useful in providing general CBC risk estimates, which could steer women away from CPM or trigger *BRCA* testing.

Last but not the least, adequate presentation of the risk estimates from the PredictCBC-1A and PredictCBC-1B is crucial for effective communication about CBC risk during doctor-patient consultations \[[@CR72], [@CR73]\]. A nomogram is an important component to communicate the risk of modern medical decision-making, although it may be difficult to use and might potentially make it more difficult to interpret the risks for laymen \[[@CR74]\] An online tool is being implemented, and a pilot study will be conducted among patients and clinicians to assess how the risk estimates from PredictCBC-1A and 1B can best be visualized to facilitate communication with patients. Other factors, which were not available in our study, predict breast cancer risk and their inclusion may further improve the discrimination and clinical utility of our CBC risk model: these factors include *CHEK2* c.1100del mutation carriers, polygenic risk scores based on common genetic variants, breast density, and reproductive and lifestyle factors such as BMI and age at menarche \[[@CR75]\]. Additional data with complete information of *BRCA1/2* mutation should be also considered in the model upgrade to reduce uncertainty of CBC risk estimates. External validation in other studies, including patients of other ethnicities, will also be important. In the meantime, our model provides a reliable basis for CBC risk counseling.

Conclusions {#Sec11}
===========

In conclusion, we have developed and cross-validated risk prediction models for CBC (PredictCBC) based on different European-descent population and hospital-based studies. The model is reasonably calibrated and prediction accuracy is moderate. The clinical utility assessment of PredictCBC showed potential for improved risk counseling, although the decision regarding CPM in the general breast cancer population remains challenging. Similar results have been found for PredictCBC version 1B, a CBC risk prediction model that calculates individualized CBC risk for first BC patients not tested for *BRCA1/2* germline mutation.
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